Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risk factors affecting the clinical course of COVID-19 in patients with lymphoid malignancies in the Omicron subvariants era - a real-world analysis by the Polish Adult Lukemia Study Group.

Annals of agricultural and environmental medicine : AAEM·2026
Same author

The preclinical discovery and development of acalabrutinib for the treatment of mantle cell lymphoma.

Expert opinion on drug discovery·2026
Same author

Autoimmune cytopenias in chronic lymphocytic leukemia in the era of novel drugs.

Expert review of hematology·2026
Same author

From covalent to reversible: the expanding role of BTK inhibitors in chronic lymphocytic leukemia.

Expert opinion on pharmacotherapy·2026
Same author

Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant.

Blood·2026
Same author

Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial.

The Lancet. Haematology·2026

Related Experiment Video

Updated: May 14, 2026

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Advancing Immunotherapy in Chronic Lymphocytic Leukemia.

Krzysztof Bieliński1, Agnieszka Wysocka2, Dawid Tyrna2

  • 1Faculty of Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland.

International Journal of Molecular Sciences
|May 13, 2026
PubMed
Summary

Novel immunotherapies are transforming chronic lymphocytic leukemia (CLL) treatment by engaging the immune system to combat cancer. These innovative approaches offer new hope for patients with difficult-to-treat or resistant CLL.

Keywords:
bispecific antibodieschimeric antigen receptor T cellschronic lymphocytic leukemiaimmunotherapymonoclonal antibodies

More Related Videos

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Related Experiment Videos

Last Updated: May 14, 2026

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Background:

  • Chronic lymphocytic leukemia (CLL) treatment has evolved from chemoimmunotherapy to targeted agents.
  • Despite advances, CLL remains incurable, marked by immune dysregulation, resistance, and toxicity.
  • Current therapies face limitations in addressing complex disease features.

Purpose of the Study:

  • To review emerging immunotherapeutic strategies for chronic lymphocytic leukemia (CLL).
  • To highlight novel approaches targeting immune-tumor interactions beyond traditional therapies.
  • To emphasize the potential of cell-engaging immunotherapies in challenging CLL cases.

Main Methods:

  • Review of current literature on CLL treatment advancements.
  • Analysis of novel immunotherapeutic modalities including antibodies and cell-based therapies.
  • Discussion of immune-tumor interactions and cytotoxicity enhancement.

Main Results:

  • Emerging immunotherapies include monoclonal antibodies, bispecific antibodies, CAR T-cells, and NK cell platforms.
  • These approaches actively engage cellular cytotoxicity, showing promise for high-risk and resistant CLL.
  • Standard pathway inhibition is often inadequate for complex CLL scenarios.

Conclusions:

  • Novel immunotherapies represent a paradigm shift in CLL treatment.
  • Optimizing the use, managing toxicity, and developing combination strategies for these therapies are crucial.
  • These cell-engaging immunotherapies are a critical priority in contemporary CLL research.